30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

First Look at Quarterly Results: 1Q12 vs. 1Q11

ORTHOWORLD’s preliminary estimates place overall 1Q12 market growth at 3% over 1Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 1Q12, unless noted otherwise. Exhi...

Biomet Fiscal 2Q12 Results

At press time, only Biomet has reported its next round of quarterly financials. The company’s year-over-year growth appears in Exhibit 2, and performance highlights follow.   Exhib...

Final 3Q11 Results: TiGenix

TIGENIX €0.6MM (~US $0.8MM) • ChondroCelect ~$0.4MM • >40% of ChondroCelect sales generated in Belgium • 5-year follow-up data from multi-center study ...

Final 3Q11 Results: Medtronic

MEDTRONIC (for 2Q12, ended 10/28/11) $839MM, -3% (U.S. $599MM, -7%; ex-U.S. $240MM, +8%) • Core Spinal $631MM, -3% (U.S. $414MM, -7%; ex-U.S. $217, +6%; Hardware -1%, Balloon kyphopla...

Final 3Q11 Results: Bacterin

BACTERIN $4.0MM, +198% • OsteoSponge 50%-60% of revenue • Received $0.24MM U.S. grant for antimicrobial orthopaedic surgical fixation devices • Signed 4 new pr...

Page Navigation